Browsing Category
Featured Articles
Recipharm acquires remaining shares in Nitin Lifesciences Ltd
Recipharm AB (publ) announces that it has reached an agreement to acquire the remaining 26 per cent of the shares of Nitin Lifesciences Limited which were owned by members of the…
Read More...
Read More...
Nanobiotix’s first immuno-oncology trial approved by U.S. FDA
Nanobiotix SA Announces that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) Application for NBTXR3, a first-in-class nanoparticle designed…
Read More...
Read More...
Avista Pharma Solutions expands Drug Product cGMP Manufacturing at Colorado Site
Avista Pharma Solutions has completed extensive facility upgrades at its Longmont, Colorado site, expanding its drug product manufacturing footprint by approximately 20,000 square feet…
Read More...
Read More...
Regeneron and ISA Pharmaceuticals announce Strategic Immuno-Oncology Collaboration
Regeneron Pharmaceuticals and ISA Pharmaceuticals announced a clinical collaboration to advance ISA101, an immunotherapy targeting human papillomavirus type 16 (HPV16)-induced cancer,…
Read More...
Read More...
Abzena secures ADC manufacturing services contract
Abzena plc has entered into a Master Services Agreement with a US biotech company to provide process development and manufacturing services to progress a novel antibody-drug conjugate…
Read More...
Read More...
Roche lymphoma drug drives high remission rate, longer survival
An experimental Roche Holding AG drug, added to standard therapy, led to a far higher rate of remission and helped patients with an advanced, aggressive blood cancer live significantly…
Read More...
Read More...
GSK submits US regulatory application for single-dose tafenoquine for P. vivax malaria
GSK and Medicines for Malaria Venture (MMV) announced the submission of a new drug application (NDA) by GSK to the United States Food and Drug Administration (FDA), seeking approval of…
Read More...
Read More...
Brammer Bio Launches Gene Therapy Product Manufacturing Operations in Massachusetts
Brammer Bio announced the completion of renovations and launch of its late-stage clinical capacity and commercial-ready cGMP manufacturing site in Cambridge, Massachusetts for gene…
Read More...
Read More...
Fresenius Kabi to Expand Pharmaceutical Manufacturing in North Carolina
Fresenius Kabi, a global health care company that specializes in medicines and technologies for infusion, transfusion and clinical nutrition, will expand its manufacturing operations in…
Read More...
Read More...
Arvinas expands strategic license agreement with Genentech
Arvinas LLC announced it has expanded its ongoing license agreement with Genentech, a member of the Roche Group, for the development of new therapeutics using Arvinas' novel PROTAC…
Read More...
Read More...
Avista Pharma Solutions Doubles API Manufacturing Capacity at Colorado Facility
Avista Pharma Solutions, Inc. has completed facility upgrades that effectively double the company’s API manufacturing capacity at its Longmont, Colorado site. During this expansion, the…
Read More...
Read More...
Cambrex invests in new small scale capacity at its Charles City, Iowa facility
Cambrex Corporation announced that it has completed an expansion of cGMP small scale capacity at its Charles City, Iowa plant.
The project has seen the installation of two 500…
Read More...
Read More...
Neurimmune collaborates with Ono Pharma in Neurodegenerative Diseases Field
Neurimmune announced that it has entered into a collaboration with Ono Pharmaceutical Co., Ltd. focused on the development of human antibodies against a novel therapeutic target for…
Read More...
Read More...
Almirall opts for Werum’s PAS-X Manufacturing Execution System
Spanish pharmaceutical company Almirall opted for Werum’s PAS-X Manufacturing Execution System to be installed in the German plant in Reinbek near Hamburg. Almirall is the market leader…
Read More...
Read More...
Fujifilm expands Biopharmaceutical Contract Development & Manufacturing Business
FUJIFILM Corporation is to invest a total of 3.2 billion yen on its CDMO sites in the U.S.A. and the U.K. in order to accelerate the expansion of the company's business for developing…
Read More...
Read More...
STELARA (ustekinumab) shows positive results in treatment of Lupus in Phase 2 Trial
Janssen Research & Development, LLC (Janssen) announced positive results from a randomized, placebo-controlled Phase 2 study investigating the anti-interleukin (IL)-12/23 monoclonal…
Read More...
Read More...
AstraZeneca provides update on tralokinumab Phase III programme in severe, uncontrolled asthma
AstraZeneca and its global biologics research and development arm, MedImmune, today announced the top-line results of the Phase III STRATOS 2 and TROPOS trials for tralokinumab, an…
Read More...
Read More...
Teva Announces Completion of PARAGARD Divestiture to CooperSurgical
Teva Pharmaceutical Industries announced that it has completed the divestiture of PARAGARD (intrauterine copper contraceptive) to CooperSurgical in a $1.1 billion cash transaction. This…
Read More...
Read More...
MilliporeSigma and Samsung BioLogics to Extend Strategic Alliance
MilliporeSigma today announced the signing of a Memorandum of Understanding (MoU) with Samsung BioLogics for a strategic alliance on biopharmaceutical manufacturing and biologics…
Read More...
Read More...
Saudi FDA approves Sobi’s Alprolix for the treatment of haemophilia B
Swedish Orphan Biovitrum AB (publ) (Sobi™) announces that the Saudi Food & Drug Authority (SFDA) in the Kingdom of Saudi Arabia has approved Alprolix (eftrenonacog alfa), for the…
Read More...
Read More...